Table 1. Characteristics of the study participants categorized by CD4 counts at ART initiation (N=356).
| Variable | <=100 | 101-200 | >200 | P-value |
|---|---|---|---|---|
| Gender: Male, n(%) | 52 (31.7) | 35 (26.3) | 14 (23.7) | 0.406 |
| Age in years: median(IQR) | 34 (29-40) | 36 (32-41) | 37 (31-45) | 0.047 |
| ART regimen:n(%) | ||||
| Stavudine/lamivudine/nevirapine | 118 (72.0) | 93 (69.9) | 46 (78.0) | |
| Zidovudine/lamivudine/efavirenz | 46 (28.0) | 40 (30.1) | 13 (22.0) | 0.516 |
| WHO stage:n(%) | ||||
| Stage I-II | 13 (7.9) | 21 (15.8) | 10 (17.0) | |
| Stage III-IV | 151 (92.1) | 112 (84.2) | 49 (83.1) | 0.062 |
| Hemoglobin:n(%) | ||||
| ≤8g/dL | 7 (4.3) | 4 (3.0) | 2 (3.4) | |
| >8 g/dL | 157 (95.7) | 129 (97.0) | 57 (96.6) | 0.841 |
| HIV RNA Viral load:n(%) | ||||
| <5 log10copies/ml | 27 (16.5) | 32 (24.1) | 27 (45.8) | |
| ≥5 log10copies/ml | 137 (83.5) | 101 (75.9) | 32 (54.2) | <0.001 |
Note: ART: Antiretroviral therapy; WHO: World Health Organization; n = number, IQR = interquartile range